Integrating Practice with Precision: A Quantitative HER2 Protein Assay Developed for Clinical Application in Trastuzumab Deruxtecan Treatment Guidance - Takeaways - MDSpire

Integrating Practice with Precision: A Quantitative HER2 Protein Assay Developed for Clinical Application in Trastuzumab Deruxtecan Treatment Guidance

  • By

  • Junmei Hao

  • Xiaochun Fei

  • Fangfang Zou

  • Qian Hu

  • Linlin Du

  • Liya Yu

  • Xuanye Bai

  • Shasha Bi

  • Qinghua Cao

  • Weishan Chen

  • Qun Dai

  • Tingting Guo

  • Hai Huang

  • Wenwei Jiang

  • Baohua Li

  • Lixia Li

  • Jingjing Liu

  • Tong Liu

  • Xiaoqin Liu

  • Jiahong Lyu

  • Yue Pan

  • Xiaoqing Shao

  • Fangrong Tang

  • Tingting Wang

  • Cuiping Zhang

  • Yongcun Zhu

  • Job Tien Chiang Liu

  • Nicole Salazar

  • Shukun Zhang

  • Jiandi Zhang

  • Xiaosong Chen

  • Chaofu Wang

  • April 27, 2026

  • 0 min

Share

  • 1

    A quantitative HER2 assay using the Quantitative Dot Blot (QDB) method was developed to improve accuracy in assessing HER2 levels for T-DXd treatment.

  • 2

    The QDB assay demonstrated higher consistency than immunohistochemistry (IHC), with an inter-rater ICC of 0.877 compared to 0.513 for IHC.

  • 3

    ROC analysis of the QDB assay achieved an AUC of 0.9477, indicating strong diagnostic performance in distinguishing HER2 levels.

  • 4

    The QDB assay identified a cutoff of 0.2746 nmole/g, achieving overall concordance rates of up to 92% in validation cohorts.

  • 5

    The study supports the QDB HER2 assay as a reliable alternative to guide T-DXd usage, particularly for distinguishing HER2-low from HER2-0.

Original Source(s)

Related Content